AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025.
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved treatments. Among its most significant offerings are the immunology drugs Skyrizi and Rinvoq, which are expected to contribute to revenue growth well into the next decade. While these drugs will eventually face patent expirations, they highlight the company’s strong track record of managing major patent losses, an essential trait for long-term success in the sector.
Since 2013, AbbVie Inc. (NYSE:ABBV) has boosted its dividend payouts by 310%. Including its history under Abbott Laboratories, the company qualifies as a Dividend King, having raised its dividends for 53 consecutive years. From its solid business foundation to its consistent dividend growth, the company appears well-positioned to support a long-term passive income strategy.
AbbVie Inc. (NYSE:ABBV) has a strong cash position, which would help the company to pay its dividend smoothly in the future. For the trailing twelve-month period, its operating cash flow came in at $16.4 billion, and levered free cash flow was $16.94 billion. The company currently offers a quarterly dividend of $1.64 per share and has a dividend yield of 3.46%, as of July 17.
While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Best Industrial Dividend Stocks to Buy Right Now and 10 Best Passive Income Stocks to Buy Now.
Disclosure: None.
